Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Altimmune's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Altimmune's regulatory disclosures and financial reporting.
Altimmune, Inc. President and CEO Jerome Benedict Durso purchased 15,000 shares of Altimmune common stock on 2026-08-13 in a purchase in open market or private transaction at $2.95 per share. Following this transaction, his directly held position increased to 62,500 shares of common stock.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on liver diseases, led by its dual glucagon/GLP-1 agonist pemvidutide for MASH, AUD and ALD. For the quarter ended June 30, 2026, it reported a net loss of $22.8 million and a six‑month net loss of $45.4 million, driven by research and development expenses of $34.8 million and general and administrative expenses of $15.6 million for the first half of 2026.
Liquidity strengthened significantly: total assets were $527.2 million, including $63.1 million of cash, cash equivalents and restricted cash, $263.3 million in short‑term investments and $192.2 million in long‑term investments, supported by a January 2026 registered direct offering and an April 2026 underwritten offering that together generated about $281.4 million in net equity proceeds. Term loan principal outstanding remained at $35.0 million.
Operationally, pemvidutide received FDA Breakthrough Therapy Designation for MASH, a global PERFORMA Phase 3 MASH trial was initiated with a 52‑week readout expected in 2029, a Phase 2 AUD trial met its primary endpoint with positive topline data, and enrollment in the RESTORE Phase 2 ALD trial was completed. Altimmune also plans to relocate its headquarters to Morristown, New Jersey under a five‑year lease with annual rent of approximately $0.3 million.
Altimmune, Inc. reported second quarter 2026 results and a business update centered on its lead candidate pemvidutide for serious liver diseases. The company highlighted initiation of the global PERFORMA Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), positive topline Phase 2 data in alcohol use disorder (AUD), and completion of enrollment in the RESTORE Phase 2 trial in alcohol-associated liver disease (ALD). Pemvidutide holds FDA Fast Track designations for MASH and AUD and Breakthrough Therapy Designation for MASH.
As of June 30, 2026, Altimmune held $519 million in cash, cash equivalents and investments, providing substantial funding for ongoing trials. Total assets were about $527.2 million and stockholders’ equity about $474.2 million. For the quarter, Altimmune generated no revenue and recorded a net loss of $22.8 million, with research and development expense of $18.7 million and general and administrative expense of $7.6 million$45.4 million. Weighted-average basic and diluted shares outstanding for the quarter were 185.4 million, reflecting a significant increase in the share count compared with the prior year.
Altimmune, Inc. reported that Chief Financial Officer Gregory L. Weaver acquired 1,753 shares of common stock on July 31, 2026 through participation in the company’s 2019 Employee Stock Purchase Plan. The shares were bought at $2.414 per share, equal to 85% of that day’s closing price, for the ESPP period from February 1 to July 31, 2026. Following this plan purchase, Weaver directly holds 39,831 shares of Altimmune common stock.
Altimmune, Inc. Chief Scientific Officer Roberts M Scot acquired 875 shares of common stock on July 31, 2026 through the company’s 2019 Employee Stock Purchase Plan. The shares were purchased at $2.414 per share, equal to 85% of that day’s closing price, bringing his direct holdings to 113,699 shares.
Altimmune reported positive topline Phase 2 results for once-weekly pemvidutide 2.4 mg in patients with moderate to severe alcohol use disorder. The study met its primary endpoint with a highly statistically significant reduction in heavy drinking days per week versus placebo and achieved multiple secondary endpoints, including a two-level reduction in World Health Organization Risk Drinking Levels, zero heavy drinking days and reductions in phosphatidyl ethanol, an objective biomarker of alcohol intake; the first two are recognized by the FDA as registrational endpoints.
Pemvidutide showed a generally favorable safety and tolerability profile, with gastrointestinal adverse events such as nausea, vomiting, diarrhea and constipation more frequent than placebo but mostly mild to moderate in severity, and similar overall treatment discontinuation rates between arms. Altimmune plans to request an End-of-Phase 2 meeting with the FDA, submit the results for scientific presentation and publication, and continue developing pemvidutide across alcohol use disorder and serious liver diseases.
Altimmune, Inc. reported that it plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year. The company describes the new area as a strong biopharmaceutical hub that it expects will support recruiting top-tier talent within its hybrid work model.
Altimmune has signed an office lease for the New Jersey headquarters, under which it will pay approximately $300,000 in rent annually over a 5-year lease term. The company states that the headquarters move is expected to help achieve cost efficiencies over the long term, while it continues its growth as a late-stage development company.
Altimmune, Inc. Schedule 13G/A reports that Tang Capital Management, LLC and related entities and persons beneficially own 666,022 shares of common stock, representing 0.3% of the class. The filing states the percent is calculated from 194,199,358 shares outstanding as of April 24, 2026 as shown in a prospectus filed on April 24, 2026. The filing lists shared voting and dispositive power among Tang Capital Management, LLC, Tang Capital Partners International, LP, and Kevin Tang, and affirms the position falls within the "Ownership of 5 Percent or Less of a Class" category.
Altimmune, Inc. reported another quarter of operating losses as it continues to advance its liver disease pipeline. For the three months ended March 31, 2026, the company generated no product revenue and recorded a net loss of $22.6 million, compared with $19.6 million a year earlier, driven by research and development spending of $16.2 million and general and administrative expenses of $8.1 million.
Altimmune’s balance sheet strengthened meaningfully, with cash, cash equivalents, restricted cash and short‑term investments totaling $331.6 million and total liabilities of $51.6 million at quarter end, supported by recent equity raises including a January 2026 registered direct offering and an April 2026 underwritten offering that brought in net proceeds of about $211.2 million and added common stock warrants with potential additional gross proceeds of $225 million if fully exercised.
The company is preparing its global PERFORMA Phase 3 trial of lead candidate pemvidutide in MASH, while running Phase 2 studies in alcohol use disorder and alcohol‑associated liver disease. With accumulated deficit of $672.0 million and ongoing negative operating cash flow, Altimmune remains dependent on its substantial cash reserves and capital markets access to fund these long, expensive clinical programs.
Altimmune, Inc. reported first quarter 2026 results and a business update focused on its lead drug pemvidutide for serious liver diseases. For the three months ended March 31, 2026, the company generated no revenue, recorded operating expenses of $24.2 million, and reported a net loss of $22.6 million (basic and diluted net loss per share of $0.18), compared with a net loss of $19.6 million a year earlier.
Cash, cash equivalents and restricted cash were $97.6 million and short-term investments were $233.9 million as of March 31, 2026, and the company highlighted total cash, cash equivalents and short-term investments of $535 million as of April 30, 2026 following a recent financing. Total assets were $335.6 million and stockholders’ equity was $284.0 million as of March 31, 2026, with 130,221,154 common shares issued and outstanding.
Altimmune plans to initiate the PERFORMA Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2026, and expects topline Phase 2 data in alcohol use disorder (AUD) and enrollment completion in the RESTORE Phase 2 alcohol-associated liver disease (ALD) trial this year. Pemvidutide holds FDA Fast Track designations for MASH and AUD, and Breakthrough Therapy Designation for MASH.